Regulation · Changelog

Peptide regulation:
the changelog

Every regulator action on peptides we could date and source, newest first. One line each, one primary link each.

Short answerRegulation · 5 min read · Updated 17 Nov 2026

Between July and 17 November 2026, the biggest change was in the US: on 28 October HHS said it will not act against licensed pharmacies and physicians compounding six peptides under ten conditions, after a July advisory vote. Australia’s TGA stepped up seizures and warnings, the UK’s MHRA acted against unlicensed weight-loss drugs, and WADA published its 2027 List.

Key takeaways

  • US: an FDA advisory committee backed six peptides in July, and HHS issued an enforcement-discretion policy for the same six in October.
  • US: FDA’s August warning letters treated “research use only” peptide products as unapproved new drugs; states moved both ways (Mississippi restricted, Louisiana protected compounding).
  • Australia: the TGA issued a public notice, seized products, reported infringement notices over alleged melanotan II supply, and stated that supplying unapproved peptides is unlawful.
  • UK: the MHRA said retatrutide sales are illegal and seized fake retatrutide and tirzepatide pens.
  • Sport: WADA’s 2027 List, in force from 1 January 2027, adds examples to S0.

01November 2026

Newest first. Each entry has a date, the jurisdiction, one line, and a link to the primary document: a regulator page, the Federal Register, legislation or an official meeting record. Jurisdictions: US, UK, AU (Australia), INT (international sport).

We found no regulator action on peptides in our three markets between 1 and 17 November. The two-week comment window opened by the Federal Register notice of 30 October has closed.

02October 2026

DateWhereWhat happenedPrimary source
30 OctUSHHS peptide policy published in the Federal Register. The Federal Register publishes notice of HHS’s “Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances” (91 FR 68526, Docket HHS-OASH-2026-0496), with a two-week comment window.Federal Register 2026-22192
28 OctUSHHS files enforcement-discretion policy for six peptides. HHS says it does not intend to act against state-licensed pharmacies, federal facilities or licensed physicians compounding BPC-157, epitalon, KPV, MOTS-c, Semax or TB-500 under ten conditions until a final rule; interim, non-binding and not an approval.HHS policy and appendices
14 OctUKMHRA seizes fake retatrutide and tirzepatide pens. MHRA and West Midlands Police seize more than 12,000 fake retatrutide and tirzepatide pens in Birmingham (announced 15 Oct); the MHRA repeats that retatrutide is not authorised in the UK.MHRA press release

03September 2026

DateWhereWhat happenedPrimary source
21 SepINTWADA publishes the 2027 Prohibited List. Approved on 10 Sep and in force from 1 Jan 2027, the 2027 List adds further examples to S0 (non-approved substances) and leaves GLP-1 receptor agonists off the List.WADA release
1 SepUSPEPTIDES for Veterans Act introduced. H.R. 10212 is introduced in the House and referred to the Committee on Veterans’ Affairs; it would direct the VA to review peptide regulations and study peptide-based therapies; it is a bill, not law.Bill text, govinfo

04August 2026

DateWhereWhat happenedPrimary source
24 AugUSFDA warning letters to online peptide sellers. FDA letters dated 24 Aug (posted 1 Sep) treat peptide products labelled “research use only” as unapproved new drugs because website evidence showed human use, and cite bacteriostatic water sold for reconstitution.FDA letter 735127
19 AugUSMississippi boards: no research-grade peptides in practice. Mississippi’s boards of medical licensure, nursing and pharmacy jointly state that healthcare providers may not compound, administer or dispense non-FDA-approved or research-grade peptides.Joint statement
17 AugAUTGA announces seizure allegedly linked to an influencer. With NSW Police (warrants executed 4 Aug), the TGA seizes more than $120,000 of peptide and steroid products allegedly linked to a social media influencer and states that importing, advertising, manufacturing and supplying unapproved peptides is unlawful.TGA media release
17 AugAUTGA safety advisory on melanotan II. TGA testing finds inconsistent amounts of melanotan II in seized nasal sprays; the advisory reports 27 infringement notices, totalling $101,412 and paid in May 2026, issued to a NSW individual for alleged unlawful supply.TGA safety advisory
1 AugUSLouisiana Act 374 takes effect. Licensing boards may not stop a Louisiana pharmacist compounding and dispensing peptides in compliance with section 503A and applicable USP chapters.Board of Pharmacy bulletin

05July 2026

DateWhereWhat happenedPrimary source
24 JulUSFDA advisory committee votes, day 2. The Pharmacy Compounding Advisory Committee backs epitalon and Semax for the 503A bulks list (outcome recorded in HHS’s October policy) and, by press report, rejects emideltide (DSIP); FDA staff had proposed rejecting all three, and FDA has not yet posted minutes.HHS policy, Appendix B
24 JulUKMHRA warns that retatrutide sales are illegal. The MHRA says retatrutide “has not been authorised for use in the UK, meaning anyone selling this product is doing so illegally.”MHRA press release
23 JulUSFDA advisory committee votes, day 1. The committee backs BPC-157, KPV, TB-500 and MOTS-c for the 503A bulks list against FDA staff proposals; reported votes 8–6–1 for the first three and 7–5–2 for MOTS-c (press-reported).HHS policy, Appendix B
20 JulAUTGA puts peptide promoters and suppliers on notice. The TGA warns promoters, importers and suppliers of unapproved peptides of compliance action and says manufacture includes “applying a label to a blank vial”.TGA media release

Vote counts are press-reported until FDA posts minutes; see the 2026 PCAC vote.

06What this log leaves out

This log lists regulatory actions only. Industry news (telehealth launches, company lawsuits), scientific papers and platform moderation are left out. So are items we could not date at a primary source. Earlier 2026 events are covered on the market pages: US, UK and Australia, with the overview at are peptides legal?

This is a plain-English summary of public documents, checked on 17 Nov 2026. It is not legal advice.

RefSources

  1. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances. Notice of availability, 91 FR 68526, Docket HHS-OASH-2026-0496. Federal Register, published 30 Oct 2026 (filed 28 Oct 2026). www.govinfo.gov/content/pkg/FR-2026-10-30/html/2026-22192.ht…
  2. HHS. Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (policy text and Appendix A). Policy document, Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…
  3. FDA. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Advisory committee calendar, content current 6 Aug 2026. www.fda.gov/advisory-committees/advisory-committee-calendar/…
  4. FDA CDER. Warning letter to Peak Performance Peptides, MARCS-CMS 735127. Warning letter, 24 Aug 2026 (posted 1 Sep 2026). www.fda.gov/inspections-compliance-enforcement-and-criminal-…
  5. Mississippi Board of Nursing, Board of Pharmacy and State Board of Medical Licensure. Joint Statement on the Prescribing of Non-FDA Approved (Research-Grade) Peptides. Joint statement, 19 Aug 2026. www.msbml.ms.gov/peptide-statement
  6. Louisiana Board of Pharmacy. Bulletin 26-01: New Laws from the 2026 Regular Session (Act 374, SB253). Board bulletin, Jul 2026. www.pharmacy.la.gov/assets/docs/Bulletins/Bulletin_26-01_New…
  7. US House of Representatives. H.R. 10212, PEPTIDES for Veterans Act, 119th Congress (introduced). Bill text, 1 Sep 2026. www.govinfo.gov/app/details/BILLS-119hr10212ih
  8. TGA. Unapproved peptide product promoters and suppliers are put on notice. Media release, 20 Jul 2026. www.tga.gov.au/news/media-releases/unapproved-peptide-produc…
  9. TGA. TGA flexes its muscle against illegal peptides and steroids. Media release, 17 Aug 2026. www.tga.gov.au/news/media-releases/tga-flexes-its-muscle-aga…
  10. TGA. Melanotan II tanning peptide products found to be inconsistently dosed. Safety advisory, 17 Aug 2026. www.tga.gov.au/safety/safety-monitoring-and-information/safe…
  11. MHRA. No summer shortcut for safe weight loss. Press release, 24 Jul 2026. www.gov.uk/government/news/no-summer-shortcut-for-safe-weigh…
  12. MHRA. Counterfeit weight loss pens worth £2 million seized by MHRA and West Midlands Police. Press release, 15 Oct 2026. www.gov.uk/government/news/counterfeit-weight-loss-pens-wort…
  13. World Anti-Doping Agency. WADA publishes 2027 Prohibited List. Release, 21 Sep 2026. www.wada-ama.org/en/news/wada-publishes-2027-prohibited-list
  14. HHS. Enforcement Discretion Policy, with Appendix B: Peptide Identities and Justifications. Policy document, Oct 2026. www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement…

Plain-English summary of public sources, not legal or medical advice. Last checked 17 Nov 2026.

Questions

What changed in peptide regulation in 2026?

In the US, a July advisory vote and an October HHS enforcement-discretion policy opened a prescription compounding route for six peptides, without approving them. Australia and the UK stepped up enforcement against unapproved and unlicensed products.

How often is this log updated?

Each entry carries its date and a primary link, and the page shows the date it was last checked.

Why are some news stories missing?

We list regulatory actions only, and only those we can date at a primary source. Press-only items are left out or clearly marked as reported.

Where is the status of each compound?

Our regulatory tracker gives compound-by-compound status; this log records the events that changed it.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page